MX368311B - Nuevos derivados de triazolopirazina y usos de los mismos. - Google Patents

Nuevos derivados de triazolopirazina y usos de los mismos.

Info

Publication number
MX368311B
MX368311B MX2016003968A MX2016003968A MX368311B MX 368311 B MX368311 B MX 368311B MX 2016003968 A MX2016003968 A MX 2016003968A MX 2016003968 A MX2016003968 A MX 2016003968A MX 368311 B MX368311 B MX 368311B
Authority
MX
Mexico
Prior art keywords
kinase activity
pharmaceutical composition
hyper
tyrosine kinase
present
Prior art date
Application number
MX2016003968A
Other languages
English (en)
Other versions
MX2016003968A (es
Inventor
Jung Jung Hee
Du Ha Jae
Rae KIM Hyoung
Yun Cho Sung
Ho Lee Kwang
Ock Lee Chong
Un Choi Sang
Hoon PARK Chi
Original Assignee
Korea Res Inst Chemical Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chemical Tech filed Critical Korea Res Inst Chemical Tech
Publication of MX2016003968A publication Critical patent/MX2016003968A/es
Publication of MX368311B publication Critical patent/MX368311B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a un nuevo derivado de triazolopirazina o una sal del mismo farmacéuticamente aceptable, y una composición farmacéutica que contiene la misma como un ingrediente activo para prevenir o tratar el trastorno hiper proliferativo. La presente invención puede ser útil como un agente terapéutico para varios trastornos hiper proliferativos asociados con la excesiva proliferación celular y crecimiento causado por la actividad de cinasa anormal, tal como cáncer, psoriasis, artritis reumatoide, y retinopatía diabética, por inhibición eficiente de la actividad de la tirosina cinasa c-Met.
MX2016003968A 2013-09-30 2013-09-30 Nuevos derivados de triazolopirazina y usos de los mismos. MX368311B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2013/008740 WO2015046653A1 (ko) 2013-09-30 2013-09-30 신규한 트리아졸로 피라진 유도체 및 그의 용도

Publications (2)

Publication Number Publication Date
MX2016003968A MX2016003968A (es) 2017-01-06
MX368311B true MX368311B (es) 2019-09-27

Family

ID=52743772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003968A MX368311B (es) 2013-09-30 2013-09-30 Nuevos derivados de triazolopirazina y usos de los mismos.

Country Status (12)

Country Link
US (1) US9403831B2 (es)
EP (1) EP3053923B1 (es)
JP (1) JP6039095B2 (es)
CN (1) CN104703988B (es)
AU (1) AU2013402175B2 (es)
BR (1) BR112016006444B1 (es)
CA (1) CA2923533C (es)
DK (1) DK3053923T3 (es)
ES (1) ES2675355T3 (es)
MX (1) MX368311B (es)
RU (1) RU2643361C2 (es)
WO (1) WO2015046653A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN113874363A (zh) 2019-04-02 2021-12-31 Array生物制药公司 蛋白质酪氨酸磷酸酶抑制剂
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20220235054A1 (en) 2021-01-27 2022-07-28 Abion Inc Novel maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same
US11964979B2 (en) * 2022-06-27 2024-04-23 Abion Inc. Camsylate salts of triazolopyrazine derivatives
US20230416255A1 (en) * 2022-06-27 2023-12-28 Abion Inc. Mesylate salts of triazolopyrazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1603570E (pt) 2003-02-26 2013-03-26 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
BRPI0514687A (pt) 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
PL1784396T3 (pl) 2004-08-26 2011-05-31 Pfizer Związki aminoheteroarylowe podstawione pirazolem jako inhibitory kinazy białkowej
JP2008531538A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
MX336996B (es) * 2009-12-31 2016-02-09 Hutchison Medipharma Ltd Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.

Also Published As

Publication number Publication date
US9403831B2 (en) 2016-08-02
EP3053923B1 (en) 2018-04-11
CA2923533A1 (en) 2015-04-02
MX2016003968A (es) 2017-01-06
BR112016006444A2 (pt) 2017-08-01
CN104703988B (zh) 2017-04-12
DK3053923T3 (en) 2018-07-23
WO2015046653A1 (ko) 2015-04-02
EP3053923A1 (en) 2016-08-10
CA2923533C (en) 2019-08-06
ES2675355T3 (es) 2018-07-10
AU2013402175B2 (en) 2017-09-07
US20150259350A1 (en) 2015-09-17
JP6039095B2 (ja) 2016-12-07
JP2015535242A (ja) 2015-12-10
AU2013402175A1 (en) 2016-04-28
EP3053923A4 (en) 2017-04-12
CN104703988A (zh) 2015-06-10
BR112016006444B1 (pt) 2021-01-19
RU2643361C2 (ru) 2018-02-01
RU2016112963A (ru) 2017-11-09

Similar Documents

Publication Publication Date Title
MX368311B (es) Nuevos derivados de triazolopirazina y usos de los mismos.
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2014193647A3 (en) Alkenyl compounds and methods of use
EP4086249A3 (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
PH12016500444A1 (en) Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
UA88315U (en) Antibacterial composition

Legal Events

Date Code Title Description
FG Grant or registration